SYMMETREL

This brand name is authorized in Australia, Hong Kong SAR China, Japan, Malta, Netherlands, New Zealand, Singapore, South Africa.

Active ingredients

The drug SYMMETREL contains one active pharmaceutical ingredient (API):

1	Amantadine UNII M6Q1EO9TD0 - AMANTADINE HYDROCHLORIDE
	Amantadine has been shown to be a low affinity antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Overactivity of glutamatergic neurotransmission has been implicated in the generation of parkinsonian symptoms. In addition, amantadine specifically inhibits the replication of influenza A viruses at low concentrations.
	Read more about Amantadine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
Symmetrel Capsules	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N04BB01	Amantadine	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BB Adamantane derivatives
Discover more medicines within N04BB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	3016R
HK	Department of Health Drug Office	00183
JP	医薬品医療機器総合機構	1161001C1089, 1161001F1050, 1161001F2057
MT	Medicines Authority	AA565/00602, AA565/55801
NL	Z-Index G-Standaard, PRK	485
NZ	Medicines and Medical Devices Safety Authority	918
SG	Health Sciences Authority	01481P
ZA	Health Products Regulatory Authority	A/20.2.8/768